|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Pipeline Insight: Orphan Diseases in CNS
Analysis of the future Huntington’s disease market with revenue forecasts of key late-stage pipeline drugs and epidemiological scenario based forecasts to 2016. Conclusions are supported by key opinion leader and industry executive comments.
Neurodegenerative Disease Drug Market Analysis & Forecasts 2007
This report provides up-to-date analysis of present and future market illustrated by substantial number of charts and figures. It also discusses strategies employed by key players in the industries. This is a must buy report, as it will provide you wi
Stakeholder Insight: Parkinsons Disease
Parkinson’s disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the s
Pipeline Insight: Depression
Analysis of drugs in late-stage clinical development for use in depression, including important clinical trial results, patient potential, market potential, and forecasts; supported by key opinion leader comments.
Central Nervous System - Epilepsy Drug Pipeline Report
Detailed information on the current drug pipeline. This report provides insight into the pipeline status of epilepsy drugs by company and by stage as well as a summary of the latest news and developments in this area.
Pipeline Insight: Orphan Diseases in CNS - Part II
The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis’s Rilutek (riluzole), facing generic incursion in 201213, future growth in this market is dependent on the success of
The CNS Market Outlook to 2013
The global CNS disorders market expanded by 8.0% from 2006, to reach total sales of $77.3bn in 2007. This growth has been primarily driven by treatments for AD, ADHD and Parkinson’s Disease.
Parkinsons Disease Market analysis and forecasts
With key some PD drugs expected to lose patent expiration in the near-term, visiongain predicts that the entry of new products will be inevitable. But which products will be successful and how much revenue will they generate?
CNS Market Trends, 2007 to 2010
The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future CNS market trends and major growth opportunities. The data and an
Commercial and Pipeline Insight: ADHD
This report provides full analysis of the current and future ADHD market, with sales forecasts to 2017 of marketed brands, generics, and key pipeline drugs in the US, 5EU, and Japan, as well as insight from key opinion leaders.
Central Nervous System - Pain Drug Pipeline Report
Detailed information on the current drug pipeline. This report provides insight into the pipeline status of pain drugs by company and by stage as well as a summary of the latest news and developments in this area.
Alzheimers Disease Market analysis and forecasts
Alzheimers disease (AD) is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stake holders.
Central Nervous System - Migraine Drug Pipeline Report
Detailed information on the current drug pipeline. This report provides insight into the pipeline status of migraine drugs by company and by stage as well as a summary of the latest news and developments in this area.
Forecast Insight: Parkinsons Disease
Provides analysis of key events and their impact on the Parkinson’s disease market since 2007. Includes an event-based, indication- and country-specific 10 year forecast of both pipeline and marketed products to 2017 in the seven major markets (
Pipeline and Commercial Insight: Alzheimers Disease
This report provides full analysis of the future Alzheimer’s disease (AD) market, with four indication- and region-specific scenario forecasts evaluating the commercial potential of pipeline and marketed drugs.
Central Nervous System - Dementia Drug Pipeline Report
Detailed information on the current drug pipeline. This report provides insight into the pipeline status of dementia drugs by company and by stage as well as a summary of the latest news and developments in this area.
CNS - Insomnia or Sleep Disorders Drug Pipeline Report
Detailed information on the current drug pipeline. This report provides insight into the pipeline status of insomnia or sleep disorders drugs by company and by stage as well as a summary of the latest news and developments in this area.
Sleep Disorders Market Analysis 2008-2018
The market penetration for insomnia drugs has not reached saturation point. Opportunities remain. But with the introduction of several new products the market is set to see changes, but expansion. This expansion is based on increased general awareness
|
